We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RTX:NYSERTX Corporation Analysis

Data as of 2026-04-29 - not real-time

$175.68

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

RTX is trading well below its discounted cash‑flow estimate, delivering a clear upside potential while the stock shows classic oversold signals. The 14‑day RSI sits deep in the oversold region and the MACD histogram remains negative, suggesting a possible short‑term bounce from the 171.6 support level. Fundamentally, the company posted 8.7% revenue growth, a healthy operating margin of 13%, and beat earnings expectations, bolstered by a new Pratt & Whitney engine contract and robust defense demand.
The dividend yield of 1.55% is supported by a payout ratio just above 50% and strong free cash flow, making the payout sustainable. With a beta of ~0.5, the stock is less volatile than the market, yet recent 30‑day volatility exceeds 25%, reflecting short‑term price swings. Overall, the combination of deep valuation discount, solid earnings momentum, and a defensible dividend profile suggests a compelling buying opportunity across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI in oversold territory indicating potential price rebound
  • Current price near strong technical support at ~171.6
  • Increasing volume supporting short‑term buying pressure

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Earnings beat and 8.7% revenue growth confirming operating strength
  • DCF fair‑value gap of >20% providing clear upside
  • New Pratt & Whitney engine contract expanding defense backlog

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term defense spending trends and diversified aerospace segments
  • Sustainable dividend supported by solid free cash flow and moderate payout
  • Strong balance sheet with manageable debt levels relative to cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth8.70%
Profit Margin8.03%
P/E Ratio33.0
ROE11.57%
ROA4.05%
Debt/Equity57.23
P/B Ratio3.6
Op. Cash Flow$11.1B
Free Cash Flow$7.2B
Industry P/E30.8

Technical Analysis

TrendNeutral
RSI28.3
Support$171.63
Resistance$205.36
MA 20$192.49
MA 50$198.05
MA 200$178.36
MACDBearish
VolumeIncreasing
Fear & Greed Index89.59

Valuation

Fair Value$80.54
Target Price$215.20
Upside/Downside22.50%
GradeUndervalued
TypeGrowth
Dividend Yield1.55%

Risk Assessment

Beta0.50
Volatility26.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.